Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy

被引:4
|
作者
Jasmiad, Nurbadriah Binti [1 ]
Abd Ghani, Rohana Binti [1 ,2 ]
Agarwal, Renu [3 ]
Ismail, Zaliha Binti [4 ]
Abdullah, Azlindarita Aisyah Mohd [5 ,6 ]
Idorus, Mohd Yusri [7 ]
机构
[1] Univ Teknol MARA UiTM, Fac Med, Dept Internal Med, Sungai Buloh, Selangor Darul, Malaysia
[2] Univ Teknol MARA UiTM, Inst Pathol Lab & Forens Med I PPerForM, Sungai Buloh, Selangor Darul, Malaysia
[3] Int Med Univ, Sch Med, Dept Pharmacol & Therapeut, Kuala Lumpur, Malaysia
[4] Univ Teknol MARA UiTM, Fac Med, Dept Publ Hlth Med, Sungai Buloh, Selangor Darul, Malaysia
[5] MSU Med Ctr, Shah Alam, Selangor Darul, Malaysia
[6] Management & Sci Univ, MSU Clin Ctr Excellence, Shah Alam, Selangor Darul, Malaysia
[7] Univ Teknol MARA UiTM, Fac Med, Inst Med Mol Biotechnol IMMB, Sungai Buloh, Selangor Darul, Malaysia
关键词
Type 2 diabetes mellitus; Diabetic retinopathy; Tissue plasminogen activator (tPA); Plasminogen activator inhibitor-1 (PAI-1); INSULIN-RESISTANCE; OBESITY; PROTEINS; PARAMETERS; PAI-1;
D O I
10.1186/s12886-022-02550-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Diabetic retinopathy (DR) is a serious complication of longstanding type 2 diabetes mellitus (T2DM), a leading cause of blindness and visual disability in the world. The aim of this study is to compare the activity of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in tears and serum of patients with DR and those without DR. Method Among the T2DM patients enrolled in this study, 26 patients had DR (n = 26) while 29 were without DR (n = 29). The blood and tear samples were obtained from all participants. The level of PAI-1 and tPA were measured in both the serum and tears. Anthropometric measurements, HbA1c, renal and lipid profile were also obtained. Results Patients with DR had significantly longer disease duration and higher systolic blood pressure compared to those without DR. Serum PAI-1 level was significantly higher in patients with DR compared to those without DR, 32.72 (IQR 32.52) vs 21.37 (IQR 14.93) ng/mL, respectively (p < 0.05). However, tear PAI-1 were comparable in both groups. Serum and tear tPA levels in both groups were also comparable (p > 0.05). Among patients with DR, there were no significant correlations between tear and serum of both biomarkers. Patients without DR showed a moderate positive correlation between serum and tear tPA levels with a coefficient of 0.363, albeit no statistical significance. Patients with DR demonstrated a significant positive correlation between levels of tears PAI-1 and BMI (r = 0.555, p = 0.026). In the group without DR, there was a statistically significant positive correlation between serum level of PAI-1 with urine albumin creatinine ratio (UACR) (r = 0.501, p = 0.013). Conclusion The present study demonstrated a significantly greater serum PAI-1 levels in patients with DR compared to those without DR. No significant correlations between tears and serum PAI-1 and tPA were observed. Thus, the role of tear biomarkers remains relevant for further investigations.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile
    Lee, SJ
    Cho, JS
    Chung, JP
    Lee, KS
    Chung, JB
    Lee, SI
    Moon, YM
    Kang, JK
    Park, IS
    GASTROENTEROLOGY, 1999, 116 (04) : A19 - A19
  • [12] Plasminogen activator inhibitor-1 and diabetic nephropathy
    Lee, HB
    Ha, H
    NEPHROLOGY, 2005, 10 : S11 - S13
  • [13] THE MECHANISM OF THE REACTION BETWEEN HUMAN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND TISSUE PLASMINOGEN-ACTIVATOR
    LINDAHL, TL
    OHLSSON, PI
    WIMAN, B
    BIOCHEMICAL JOURNAL, 1990, 265 (01) : 109 - 113
  • [14] NEUTRALIZATION BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 OF MUTANTS OF TISSUE PLASMINOGEN-ACTIVATOR
    BERGUM, PW
    ERICKSON, LA
    ENZYME, 1988, 40 (2-3) : 122 - 129
  • [15] Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1
    Asselbergs, Folkert W.
    Pattin, Kristine
    Snieder, Harold
    Hillege, Hans L.
    van Gilst, Wiek H.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (06): : 562 - 568
  • [16] Plasminogen activator inhibitor-1
    Gils, A
    Declerck, PJ
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2323 - 2334
  • [17] Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina
    Habib, Syecl Shahid
    Gader, Abdel Galil Mohamad Abdel
    Kurdi, Mohammad Ibrahim
    Suriya, Mohammad Owais
    Al Aseri, Zohair
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2012, 62 (07) : 681 - 685
  • [18] Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor-1
    Björquist, P
    Ehnebom, J
    Deinum, J
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1999, 1431 (01): : 24 - 29
  • [19] Regulation of Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 by Hydrocortisone in Rat Primary Astrocytes
    Kwon, Kyoung Ja
    Cho, Kyu Suk
    Lee, Sung Hoon
    Kim, Jung Nam
    Joo, So Hyun
    Ryu, Jong Hoon
    Ignarro, Louis J.
    Han, Seol-Heui
    Shin, Chan Young
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (07) : 1059 - 1069
  • [20] Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schonlein purpura
    Besbas, N
    Erbay, A
    Saatci, U
    Ozdemir, S
    Bakkaloglu, A
    Ozen, S
    Topaloglu, R
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1998, 16 (01) : 95 - 98